AR035676A1 - Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina - Google Patents
Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandinaInfo
- Publication number
- AR035676A1 AR035676A1 ARP010105888A ARP010105888A AR035676A1 AR 035676 A1 AR035676 A1 AR 035676A1 AR P010105888 A ARP010105888 A AR P010105888A AR P010105888 A ARP010105888 A AR P010105888A AR 035676 A1 AR035676 A1 AR 035676A1
- Authority
- AR
- Argentina
- Prior art keywords
- effective amount
- pyrazolo
- prostaglandin
- acid
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Formulación farmacéutica que contiene al menos una pirazolo [4,3-d]pirimidina de fórmula (1) donde R1, R2 son cada uno, independientemente entre sí, H, A, OH, OA, o Hal, R1 y R2 juntos, son tambien alquileno C3-5, -O-CH2-CH2, -CH2-O-CH2, -O-CH2-O- o -O-CH2-CH2-O-, R3, R4 son cada uno, independientemente entre sí H, o A, X es R5, R6 o R7 monosustituido con R8, R5 es alquileno de cadena recta o ramificada C1-10 donde uno o dos grupos CH2 pueden estar reemplazados por grupos CH=CH, O, S o SO, R6 es cicloalquilo o cicloalquilalquileno C5-12, R7 es fenilo o fenilmetilo, R8 es COOH, COOA, CONH2, CONHA, CON(A)2, o CN, A es alquilo C1-6 y Hal es F, Cl, Br o I y/o sus sales y/o solvatos aceptables para uso farmacéutico, y a) por lo menos un antitrombótico o b) por lo menos un antagonista del calcio o c)por lo menos una prostaglandina o un derivado de prostaglandina. Los compuestos de fórmula (1) presentan una inhibición específica de la fosfodiesterasa GMPc (PDE V) . también se describe: 1) un conjunto (Kit) que en envases separados comprende (a) una cantidad efectiva de ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético y (b) una cantidad efectiva de un antitrombótico; 2) un conjunto (Kit) que en envases separados comprende a) una cantidad efectiva de sal de etanolamina del ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético, y b) una cantidad efectiva de un antagonista de calcio; 3)un conjunto (kit) que en envases separados comprende a) una cantidad efectiva de sal de etanolamina del ácido [7-(3-cloro-4-metoxi-bencilamino)-1-metil-3-propil-1H-pirazolo[4,3-d]-pirimidin-5-ilmetoxi]-acético, y b) una cantidad efectiva de una prostaglandina o un derivado de prostaglandina. La formulación farmacéutica anteriormente mencionada se usa para preparar un medicamento para el tratamiento de angina, hipertensión, hipertensión pulmonar, deficiencia cardíaca congestiva (CHF), enfermedad pulmonar obstructiva crónica (COPD), Cor pulmonar, insuficiencia cardíaca derecha, arterioesclerosis, reducción de la circulación en los vasos cardíacos, enfermedades vasculares periféricas, apoplejía, bronquitis, asma alérgico, asma crónico, rinitis alérgica, glaucoma, síndrome de colon irritable, tumores, insuficiencia renal, cirrosis, hepática y para el tratamiento de desórdenes sexuales femeninos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10063224A DE10063224A1 (de) | 2000-12-19 | 2000-12-19 | Pharmazeutische Formulierung enthaltend Pyrazolo(4,3-d)pyrimidine und Antithrombotica |
| DE2000163882 DE10063882A1 (de) | 2000-12-21 | 2000-12-21 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Calcium-Antagonisten |
| DE2000164993 DE10064993A1 (de) | 2000-12-23 | 2000-12-23 | Pharmazeutische Formulierung enthaltend Pyrazolo[4,3-d]pyrimidine und Prostaglandine oder Prostaglandinderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035676A1 true AR035676A1 (es) | 2004-06-23 |
Family
ID=27214208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105888A AR035676A1 (es) | 2000-12-19 | 2001-12-19 | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040063730A1 (es) |
| EP (1) | EP1343506A1 (es) |
| JP (1) | JP2004516270A (es) |
| KR (1) | KR20030059349A (es) |
| CN (1) | CN1481244A (es) |
| AR (1) | AR035676A1 (es) |
| AU (1) | AU2002229573A1 (es) |
| BR (1) | BR0115995A (es) |
| CA (1) | CA2431077A1 (es) |
| CZ (1) | CZ20031776A3 (es) |
| HU (1) | HUP0303315A2 (es) |
| MX (1) | MXPA03005393A (es) |
| NO (1) | NO20032773L (es) |
| PL (1) | PL362513A1 (es) |
| SK (1) | SK8192003A3 (es) |
| WO (1) | WO2002049651A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035531A1 (es) * | 2001-01-22 | 2004-06-02 | Novartis Ag | Composicion para el control de plagas endoparasiticas en ganados y animales domesticos, un metodo para su control y el uso de dicha composicion para la preparacion de medicamentos |
| DK1348707T3 (da) * | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| KR100468352B1 (ko) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
| JP4015176B2 (ja) | 2003-04-29 | 2007-11-28 | ファイザー・インク | 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類 |
| US7732467B2 (en) * | 2003-05-15 | 2010-06-08 | Alzheimer's Institute Of America, Inc. | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| GB0327323D0 (en) * | 2003-11-24 | 2003-12-31 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| BRPI0509731A (pt) * | 2004-04-07 | 2007-09-25 | Pfizer | pirazol[4,3-d]pirimidinas |
| EP2139462B1 (en) * | 2007-03-30 | 2014-01-22 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| ES2449594T3 (es) * | 2007-10-05 | 2014-03-20 | Alzheimer's Institute Of America, Inc. | Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina |
| US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
| HUE047767T2 (hu) * | 2008-08-13 | 2020-05-28 | Actelion Pharmaceuticals Ltd | Macitentánt tartalmazó terápiás készítmények |
| CN115282152A (zh) * | 2015-01-28 | 2022-11-04 | 瑞采生技有限公司 | 用于增强PPARγ表现及核转位之化合物及其医疗用途 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US10266530B2 (en) | 2016-09-09 | 2019-04-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2018195397A2 (en) * | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
| IL293326A (en) | 2019-11-26 | 2022-07-01 | Ikena Oncology Inc | Polymorphic Carbazole History and Uses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353285A1 (fr) * | 1975-09-17 | 1977-12-30 | Doms Laboratoires | Medicament vasodilatateur coronarien perfectionne |
| JPS5459266A (en) * | 1977-10-14 | 1979-05-12 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analogs and their preparation |
| FR2568774B2 (fr) * | 1984-05-30 | 1989-05-19 | Choay Sa | Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique |
| FR2672601B1 (fr) * | 1991-02-08 | 1994-10-14 | Synthelabo | Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique. |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| DE19709877A1 (de) * | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| AU734734B2 (en) * | 1997-10-28 | 2001-06-21 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| DE10058662A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Pyrazolo[4,3-d]pyrimidinen |
| DE10103647A1 (de) * | 2001-01-27 | 2002-08-01 | Merck Patent Gmbh | Verfahren zur Herstellung eines Pyrazolo (4,3-d) pyrimidinderivates |
-
2001
- 2001-11-28 CZ CZ20031776A patent/CZ20031776A3/cs unknown
- 2001-11-28 US US10/451,105 patent/US20040063730A1/en not_active Abandoned
- 2001-11-28 EP EP01990452A patent/EP1343506A1/de not_active Withdrawn
- 2001-11-28 MX MXPA03005393A patent/MXPA03005393A/es not_active Application Discontinuation
- 2001-11-28 JP JP2002550991A patent/JP2004516270A/ja active Pending
- 2001-11-28 CN CNA018209165A patent/CN1481244A/zh active Pending
- 2001-11-28 AU AU2002229573A patent/AU2002229573A1/en not_active Abandoned
- 2001-11-28 CA CA002431077A patent/CA2431077A1/en not_active Abandoned
- 2001-11-28 WO PCT/EP2001/013916 patent/WO2002049651A1/de not_active Application Discontinuation
- 2001-11-28 BR BR0115995-0A patent/BR0115995A/pt not_active Application Discontinuation
- 2001-11-28 HU HU0303315A patent/HUP0303315A2/hu unknown
- 2001-11-28 PL PL01362513A patent/PL362513A1/xx unknown
- 2001-11-28 KR KR10-2003-7008078A patent/KR20030059349A/ko not_active Application Discontinuation
- 2001-11-28 SK SK819-2003A patent/SK8192003A3/sk unknown
- 2001-12-19 AR ARP010105888A patent/AR035676A1/es unknown
-
2003
- 2003-06-18 NO NO20032773A patent/NO20032773L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20030059349A (ko) | 2003-07-07 |
| NO20032773D0 (no) | 2003-06-18 |
| MXPA03005393A (es) | 2003-09-25 |
| AU2002229573A1 (en) | 2002-07-01 |
| JP2004516270A (ja) | 2004-06-03 |
| US20040063730A1 (en) | 2004-04-01 |
| CN1481244A (zh) | 2004-03-10 |
| CA2431077A1 (en) | 2002-06-27 |
| SK8192003A3 (en) | 2003-10-07 |
| HUP0303315A2 (hu) | 2004-01-28 |
| BR0115995A (pt) | 2004-01-13 |
| NO20032773L (no) | 2003-06-18 |
| WO2002049651A1 (de) | 2002-06-27 |
| EP1343506A1 (de) | 2003-09-17 |
| PL362513A1 (en) | 2004-11-02 |
| CZ20031776A3 (cs) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035676A1 (es) | Formulacion farmaceutica que contiene pirazolo[4,3-d]pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| ES2386461T3 (es) | Pteridinas, útiles como inhibidores del VHC, y métodos para su preparación | |
| ES2341572T3 (es) | Pirido(2,3-d)-pirimidinas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas. | |
| RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
| AR106717A1 (es) | Composiciones para tratar atrofia muscular espinal, kits, métodos de tratamiento, usos | |
| RU2003117478A (ru) | Применение тиенопиримидинов | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| AR087241A2 (es) | Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
| RU2014109451A (ru) | Производные тетрагидротриазолопиримидина в качестве ингибиторов нейтрофильной эластазы человека | |
| PE20051061A1 (es) | 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS | |
| CA2192470A1 (en) | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf | |
| ECSP067111A (es) | Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica | |
| JP2017523219A5 (es) | ||
| AR036864A1 (es) | Uso de compuestos de acido benzacepin-n-acetico, y procedimiento para la preparacion de dichos compuestos | |
| RU2004114239A (ru) | Производные пиримидина | |
| HRP20100681T1 (hr) | Derivati hinaholina korisni za tretman periferne arterijske bolesti i kao inhibitori fosfodiesteraze | |
| AR035373A1 (es) | Uso de pirazolo(4,3-d]pirimidinas | |
| AR035741A1 (es) | Formulacion farmaceutica que comprende pirazolo (4,3-d)pirimidinas y nitratos o tienopirimidinas y nitratos, una preparacion farmaceutica a base de estos componentes, y un conjunto de elementos (kit) que contiene estos componentes en envases independientes. | |
| AR032009A1 (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
| AR035675A1 (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandinas, el uso de las mismas para preparar un medicamento , y un conjunto (kit) que contiene los componentes de la formulacion en envases separados | |
| US20030171393A1 (en) | Drugs for sex dysfunctions | |
| JP2007509099A5 (es) | ||
| RU2447074C2 (ru) | Птеридины, полезные в качестве ингибиторов hcv, и способы получения птеридинов | |
| AR025645A1 (es) | Uso de tienopirimidinas | |
| RU2003124067A (ru) | Фармацевтическая композиция, содержащая пиразоло[4,3-d]пиримидины и нитраты или тиенопиримидины и нитраты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |